Bionomics discontinues BNC210 for PTSD after Phase II miss

By Jaime De Leon | Oct 5, 2018 | 8:19 PM GMT

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary